Coherus BioSciences (CHRS) Misses Q4 EPS by 19c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.49 +0.68%
EPS Growth %: +23.5%
Financial Fact:
Selling, general, and administrative expenses: 137.78M
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: +23.5%
Financial Fact:
Selling, general, and administrative expenses: 137.78M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of $0.53, $0.19 worse than the analyst estimate of $0.72. Revenue for the quarter came in at $123.9 million versus the consensus estimate of $123.01 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
- Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
